Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) has submitted a New Drug Application to the US Food and Drug Administration (FDA) for carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older.

 

The filing is supported by data from three placebo-controlled clinical trials in patients with epilepsy. Results from the first study were presented at the Ninth EILAT Conference on Antiepileptic Drugs in June and results from two additional studies will be presented at the annual meeting of the American Epilepsy Society later this year. Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD) is a subsidiary of Johnson & Johnson, the world's most broadly-based producer of health care products.